Andrew McKenzie and Emma Sturgill, PhD, Sarah Cannon Research Institute, Nashville, TN, outline future advances in the care of patients with breast cancer, including increased use of next-generation sequencing in precision medicine, liquid biopsies and the importance of genomics for the development of new targeted therapies. Dr Sturgill discusses triple-negative breast cancer and the role of genomics in this patient population who have historically exhibited a poorer prognosis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).